HSBC Holdings’s Silence Therapeutics SLN Stock Holding History

HSBC Holdings’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$640K	Sell	122,834 -50,000	-29%	-$275K	﹤0.01%	2098
2025 Q4	$1.07M	Sell	172,834 -39	-0%	-$250	﹤0.01%	1896
2025 Q3	$909K	Buy	172,873 +39	+0%	+$217	﹤0.01%	1837
2025 Q2	$1.02M	Hold	172,834	–	–	﹤0.01%	1786
2025 Q1	$499K	Hold	172,834	–	–	﹤0.01%	2082
2024 Q4	$1.19M	Sell	172,834 -5,000	-3%	-$64.5K	﹤0.01%	1702
2024 Q3	$3.23M	Hold	177,834	–	–	﹤0.01%	1264
2024 Q2	$3.41M	Hold	177,834	–	–	﹤0.01%	1196
2024 Q1	$3.84M	Hold	177,834	–	–	﹤0.01%	1199
2023 Q4	$3.14M	Hold	177,834	–	–	﹤0.01%	1314
2023 Q3	$1.74M	Hold	177,834	–	–	﹤0.01%	1515
2023 Q2	$989K	Hold	177,834	–	–	﹤0.01%	1721
2023 Q1	$1.12M	Hold	177,834	–	–	﹤0.01%	1715
2022 Q4	$2.74M	Hold	177,834	–	–	﹤0.01%	1549
2022 Q3	$1.75M	Hold	177,834	–	–	﹤0.01%	1609
2022 Q2	$2.07M	Hold	177,834	–	–	﹤0.01%	1570
2022 Q1	$3.47M	Sell	177,834 -1,456	-0.8%	-$29K	﹤0.01%	1341
2021 Q4	$4.28M	Buy	+179,290	New	+$4.15M	﹤0.01%	1331

Other funds holding SLN

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

HSBC Holdings's SLN Position: Q1 2026 in Review

HSBC Holdings reduced its Silence Therapeutics (SLN) stake by 29% in Q1 2026, selling an estimated $275K and leaving 122,834 shares worth $640K. The position accounts for ﹤0.01% of the portfolio, ranked #2098.

HSBC Holdings first reported a position in SLN in Q4 2021 and has held it in 18 quarters since. The position peaked at $4.28M in Q4 2021. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

HSBC Holdings held 122,834 shares of Silence Therapeutics worth $640K as of Q1 2026.
HSBC Holdings sold 50,000 Silence Therapeutics shares in Q1 2026, an estimated $275K.
Silence Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2098 holding.
HSBC Holdings first reported a position in Silence Therapeutics in Q4 2021 and has held it in 18 quarters since.
HSBC Holdings's Silence Therapeutics position peaked at $4.28M in Q4 2021.
56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.